Pharmaceuticals company Supriya Lifescience Q2FY27 results

Q2FY27 Quarterly Result Announced for Supriya Lifescience Ltd. SUPRIYA Pharmaceuticals company Supriya Lifescience announced Q2FY27 results Financial Highlights: Revenue from operations: Standalone Revenue from operations for Q2FY27 stood at Rs 2,062.97 million, registering a YoY increase of 3.23% over Rs 1,998.33 million in Q2FY26 and a QoQ growth of 8.72% over Rs 1,897.47 million in Q1FY27. For H1FY27, Standalone Revenue from operations stood at Rs 3,960.44 million, up 14.83% YoY from Rs 3,449.07 million in H1FY26. Total income: For Q2FY27, Standalone Total income reached Rs 2,085.89 million, marking a YoY increase of 2.98% from Rs 2,025.58 million in Q2FY26 and a QoQ growth of 8.42% from Rs 1,923.95 million in Q1FY27. For H1FY27, Standalone Total income was Rs 4,009.84 million, showing a YoY increase of 14.47% compared to Rs 3,503.06 million in H1FY26. Profit Before Tax (PBT): Standalone PBT during Q2FY27 was recorded at Rs 377.78 million, lower by 44.70% YoY against Rs 683.18 million in Q2FY26 and down 7.39% QoQ from Rs 407.92 million in Q1FY27. For H1FY27, Standalone PBT stood at Rs 785.70 million, down 32.11% YoY from Rs 1,157.30 million in H1FY26. Profit After Tax (PAT): Net profit for Q2FY27 stood at Rs 292.50 million, reflecting a YoY drop of 41.99% against Rs 504.27 million in Q2FY26 but an expansion of 21.66% QoQ compared to Rs 240.43 million in Q1FY27. For H1FY27, cumulative Standalone PAT was Rs 532.93 million, down 37.46% YoY over Rs 852.17 million in H1FY26. Earnings Per Share (EPS): Standalone basic and diluted EPS for Q2FY27 was reported at Rs 3.63, a YoY reduction of 42.11% from Rs 6.27 in Q2FY26 but a QoQ improvement of 21.40% from Rs 2.99 in Q1FY27. For H1FY27, Standalone basic and diluted EPS reached Rs 6.62 compared to Rs 10.59 in H1FY26. All this is for information This is not a buy/sell recommendation. SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Thank you, Technofunda24